دورية أكاديمية

Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer.

التفاصيل البيبلوغرافية
العنوان: Alantolactone: A Natural Plant Extract as a Potential Therapeutic Agent for Cancer.
المؤلفون: Cai, Yuan, Gao, Kewa, Peng, Bi, Xu, Zhijie, Peng, Jinwu, Li, Juanni, Chen, Xi, Zeng, Shuangshuang, Hu, Kuan, Yan, Yuanliang
المصدر: Frontiers in Pharmacology; 11/26/2021, Vol. 12, p1-10, 10p
مصطلحات موضوعية: PLANT extracts, CELLULAR signal transduction, COLORECTAL cancer, BREAST cancer, ANTINEOPLASTIC agents, BIOAVAILABILITY
مستخلص: Alantolactone (ALT) is a natural compound extracted from Chinese traditional medicine Inula helenium L. with therapeutic potential in the treatment of various diseases. Recently, in vitro and in vivo studies have indicated cytotoxic effects of ALT on various cancers, including liver cancer, colorectal cancer, breast cancer, etc. The inhibitory effects of ALT depend on several cancer-associated signaling pathways and abnormal regulatory factors in cancer cells. Moreover, emerging studies have reported several promising strategies to enhance the oral bioavailability of ALT, such as combining ALT with other herbs and using ALT-entrapped nanostructured carriers. In this review, studies on the anti-tumor roles of ALT are mainly summarized, and the underlying molecular mechanisms of ALT exerting anticancer effects on cells investigated in animal-based studies are also discussed. [ABSTRACT FROM AUTHOR]
Copyright of Frontiers in Pharmacology is the property of Frontiers Media S.A. and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
قاعدة البيانات: Complementary Index
الوصف
تدمد:16639812
DOI:10.3389/fphar.2021.781033